Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence

Table 1 Overview of studies included in the meta-analysis

Ref.	Sample size	Study phase	Study type	Article type	Randomization	NI	Cycles of NI	ICI post-surgery
Bai et al[20], 2022	24	2	Clinical trial	Conference abstract	Randomized	Camrelizumab + apatinib (n = 13)	4	Yes
Chen et al[21], 2022	11	2	Clinical trial	Conference abstract	Non-randomized	Tislelizumab	2	Yes
Cheung et al[30], 2024	20	/	Clinical trial	Full text	/	Nivolumab	3	/
D'Alessio et al[22], 2022	17	1b	Clinical trial	Conference abstract	/	Nivolumab + ipilimumab	2	/
Kaseb et al[23], 2022	30	2	Clinical trial	Full text	Randomized	Nivolumab (n = 13) or nivolumab + ipilimumab (n = 14)	3	Yes
Marron et al[27], 2022	21	2	Clinical trial	Full text	/	Cemiplimab	2	Yes
Ming et al[31], 2024	14	2	Clinical trial	Conference abstract	/	Tislelizumab + lenvatinib	2	Yes
Shi et al[24], 2021	18	1b/2	Clinical trial	Conference abstract	Randomized	Toripalib (n = 10) or toripalib + lenvatinib (n = 8)	1	Yes
Song et al[25], 2023	24	2	Clinical trial	Conference abstract	/	Tislelizumab + lenvatinib	4	Yes
Sun et al[26], 2022	30	2	Clinical trial	Conference abstract	/	Sintilimab + bevacizumab	N/A	/
Wang et al[28], 2022	20	/	Retrospective study	Full text	/	Apatinib + camrelizumab	N/A	/
Xia et al[29], 2022	18	2	Clinical trial	Full text	/	Camrelizumab +apatinib	3	Yes

Summary of study characteristics, including sample size, study type, immunotherapy regimen, number of cycles, and postoperative treatment. NI: Neoadjuvant immunotherapy; ICI: Immune checkpoint inhibitor.